| Alimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. Co. commercially markets ILUVIEN in the United States, Germany, the United Kingdom, Portugal and Ireland. Co. has three segments: the United States, International and Other. We show 47 historical shares outstanding datapoints in our coverage of ALIM's shares outstanding history.|
Understanding the changing numbers of ALIM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALIM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALIM by allowing them to research ALIM shares outstanding history
as well as any other stock in our coverage universe.